Bioelectronica
A research-stage biotechnology company building next-generation digital tools for drug discovery, diagnostics, and cell sorting.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
$16.0m | Series A | ||
| Total Funding | 000k | ||
Related Content
Bioelectronica is a research-stage biotechnology company focused on developing intelligent digital tools for drug discovery, cell screening, and cell sorting. Founded by Roger Chen and Jonathan Hull, the company leverages advanced technologies such as computer vision, biochemical reagents, and consumer electronics to accelerate the drug discovery process. Bioelectronica's flagship product, the Hypercell technology platform, offers high throughput digital biochemistry capabilities that enable quick and cost-effective analysis and sorting of cells, particularly secretors. This platform has been recognized for its innovation, notably being selected by the Society for Laboratory Automation and Screening as the most innovative new product in January 2020. Bioelectronica operates on a contract basis, providing cell sorting and analysis services to laboratories and research institutions. The company generates revenue through service contracts and sales of its proprietary technology. Bioelectronica serves clients in the life sciences sector, including pharmaceutical companies, academic institutions, and research labs, aiming to enhance their research capabilities and accelerate scientific discoveries.
Keywords: digital biochemistry, cell sorting, drug discovery, computer vision, biochemical reagents, high throughput, life sciences, research-stage, biotechnology, Hypercell.